NASDAQ : BHST

BioHarvest Sciences Inc. Common Stock — News

$2.16 USD

$0.02 (0.93%)

Volume
47.98K
Average Volume
40.16K
Market Capitalization
$37.43M
P/E Ratio
-3.48
Dividend Yield
0.00%
Price Target
$10.00
Year High
$12.80
Year Low
$1.82
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.96
Source Headline
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 29, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will present at the upcoming Canaccord Genuity 46th Annual Growth Conference, to be held on August 11-13, 2026, in Boston, Massachusetts. In addition to presenting, Dr. Rakib will also be participating in one-on-one investor meetings from August 11-12.

newsfilecorp.com - 2026-07-29 08:00:00

BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 28, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will report its second quarter 2026 financial results before the market opening on Tuesday, August 11, 2026. The Company will host a conference call and webcast at 8:00 AM Eastern Time to discuss the results and provide an update on business operations.

newsfilecorp.com - 2026-07-28 08:00:00

BioHarvest lands $1.4M grant for AI-driven plant science

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said on Wednesday it has received a 4.33 million NIS (about $1.4 million) grant from the Israel Innovation Authority to fund a new research initiative applying machine learning and computer vision to its plant cell culture programs. The non-dilutive funding, BioHarvest's second grant from the IIA this year, will support integration of data science, chemo-informatics and high-throughput digital sensing into the company's biological development workflows, aiming to move plant cell culture away from trial-and-error methods toward a data-driven optimization framework.

proactiveinvestors.com - 2026-07-15 08:51:54

BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis

Grant will partially fund research to enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest's CDMO customers and partners Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 15, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest's biological development workflows, thereby accelerating its plant cell culture programs.

newsfilecorp.com - 2026-07-15 07:30:00

BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026. Presentation Details: Date/Time: Wednesday, July 22, 2026 at 10:00 a.m.

newsfilecorp.com - 2026-07-13 08:00:00

BioHarvest Sciences to Present at the 2026 BIO International Convention

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - June 18, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that it will present at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, California. Presentation Details: Session: Company Presentation Date/Time: Wednesday, June 24, 11:45 AM Location: Theater 3 BioHarvest Sciences' presentation will showcase its proprietary Botanical Synthesis™ platform, which enables the production of plant-derived compounds with pharmaceutical-grade precision, consistency, and commercial scalability, opening new possibilities in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics.

newsfilecorp.com - 2026-06-18 07:30:00

BioHarvest Sciences and Tate & Lyle expand sweetener development program

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) announced that it has expanded its collaboration with Tate & Lyle PLC (LSE:TATE) to broaden the scope of their joint sweetener development program to include multiple plant-based sweetener molecules. The expanded partnership builds on an agreement signed in 2024 and follows what the companies described as strong technical progress in developing sweetening solutions for food and beverage manufacturers.

proactiveinvestors.com - 2026-05-19 08:41:38

Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation

Expanded sweetener molecule development program aims to broaden access to plant-based sweetening solutions tailored to diverse customer food and beverage categories. Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 18, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced the expansion of its collaboration with Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, broadening the scope of their joint sweetener development program to include multiple plant-based sweetener molecules.

newsfilecorp.com - 2026-05-18 07:00:00

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

BioHarvest Sciences Inc. (BHST) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-14 13:50:47

BioHarvest Sciences Q1 Earnings Call Highlights

BioHarvest Sciences NASDAQ: BHST reported higher first-quarter revenue and reiterated its 2026 outlook as management detailed a broader reorganization around two business lines: its direct-to-consumer VINIA products business and its contract development and manufacturing organization, or CDMO, platform.

marketbeat.com - 2026-05-14 10:09:45

BioHarvest Sciences Q1 revenue climbs as it expands botanical synthesis pipeline

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) reported an 8% jump in first quarter revenue as the company advanced several contract development and manufacturing organization (CDMO) projects and expanded its direct-to-consumer wellness business. The company posted first quarter revenue of $8.5 million, up from $7.9 million a year earlier, while maintaining its full-year revenue guidance range of $42 million to $48 million.

proactiveinvestors.com - 2026-05-14 08:53:27

BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Beats Revenue Estimates

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

zacks.com - 2026-05-14 08:11:06

BioHarvest Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

Quarterly revenue up 8% year over year; Annual revenue guidance range remains at $42-$48 million CDMO fragrance and Saffron projects reach successful milestones; First quarter CDMO revenue grew 135% YoY VINIA brand customer base grows to 90,000 active users as of the end of April Two-lens framework enacted in Q1 to optimize performance across CDMO and D2C businesses Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 14, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis™ technology and sustainable plant-based molecule development, today announced its first quarter 2026 financial results. The Company will hold a conference call this morning at 8:00 am Eastern Daylight Time (EDT) to discuss the results and provide an update on business operations.

newsfilecorp.com - 2026-05-14 07:00:00

BioHarvest Sciences Appoints New Head of Business Development for its CDMO Division

Business development appointment is aligned with securing long-term customers for development and manufacturing partnerships Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced the appointment of Nedira Salzman-Frenkel to Vice President of Business Development. Ms. Salzman-Frenkel's role will be instrumental for sourcing and managing new prospective contracts across the pharmaceutical, nutraceutical, nutrition, and cosmetic areas for BioHarvest's contract development and manufacturing organization (CDMO) business.

newsfilecorp.com - 2026-05-13 17:32:00

BioHarvest Sciences advances synthetic saffron program with SaffronTech partnership

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) said that it has completed the first stage of a multi-stage development agreement with SaffronTech, establishing a stable saffron cell bank that the company says could one day offer a sustainable alternative to one of the world's most expensive agricultural commodities. The Nasdaq-listed biotech said completion of Stage 1 has triggered the start of Stage 2 under the ongoing agreement, which will focus on using its patented Botanical Synthesis platform to generate enough biomass to support pre-commercial testing and product development for nutraceutical and culinary applications.

proactiveinvestors.com - 2026-05-13 09:50:24

BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications

- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Columbia and Rehovot, Israel---(Newsfile Corp. - May 13, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has completed Stage 1 under a multi-stage development agreement, successfully establishing a stable saffron cell bank for potential nutraceutical and culinary applications. The development partner is SaffronTech, a company pioneering advanced cultivation methods for saffron, one of the world's most valuable and health-promoting botanicals.

newsfilecorp.com - 2026-05-13 08:00:00

Alibaba shares jump as AI cloud surge offsets mixed quarterly results

Alibaba Group (NYSE:BABA) shares climbed nearly 7% in early Wednesday trading after the Chinese e-commerce and technology giant reported fourth-quarter...

proactiveinvestors.com - 2026-05-13 06:57:00

BioHarvest Sciences wins $1.2M fragrance contract

BioHarvest Sciences Inc (NASDAQ:BHST, FRA:8MV0) has secured a $1.2 million Stage 2 contract to develop a rare scent-producing plant compound for the global fragrance industry, marking a key step in the firm's push into a market the company values at $23 billion. The contract, awarded by a United Arab Emirates-based investment group, is part of a multi-stage development program for a fragrance raw material described as among the most valuable in the world, with premium grades fetching tens of thousands of dollars per kilogram.

proactiveinvestors.com - 2026-05-12 09:12:35

Plug Power reports first quarter earnings beat on narrower losses, margins progress

Plug Power (NASDAQ:PLUG) reported first quarter 2026 results that exceeded revenue expectations and showed continued improvement in profitability metrics,...

proactiveinvestors.com - 2026-05-12 08:57:00

BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform

Source plant is widely regarded as one of the most valuable fragrance raw materials in the world Stage 2 contract follows successful Stage 1 completion in March 2026 Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has signed a $1.2 million-dollar Stage 2 contract as part of a multi-stage development program for a rare scent-producing plant used in the global fragrance industry. This scent is widely regarded as one of the most valuable fragrance raw materials in the world, with premium grades commanding prices exceeding tens of thousands of U.S. dollars per kilogram and demand growing across the Middle East, Asia, and luxury Western perfume markets.

newsfilecorp.com - 2026-05-12 07:30:00

Will BioHarvest Sciences Inc. (BHST) Report Negative Earnings Next Week? What You Should Know

BioHarvest Sciences Inc. (BHST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-05-07 11:00:48

Get BHST Insider Trade Alerts

BHST Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$0.00

0 analysts

Last Year

$10.00

1 analysts

All Time

$12.33

3 analysts

BHST Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2025-04-08 HC Wainwright & Co. Maintain Buy Buy